
    
      This is an open-label, Phase 1 dose escalation study of NOV140101 (IDX-1197) to evaluate the
      safety, tolerability, pharmacokinetics, pharmacodynamics and the anti-tumor efficacy of
      IDX-1197 in patients with advanced solid tumors after failure of standard of care. DLTs will
      be assessed as the primary endpoint in this trial.
    
  